The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.
 
Richard Francis Dunne
Consulting or Advisory Role - Exelixis
 
Nicholas A. Ullman
No Relationships to Disclose
 
Brian A. Belt
No Relationships to Disclose
 
Luis I. Ruffolo
No Relationships to Disclose
 
Paul Burchard
No Relationships to Disclose
 
Aram F Hezel
Consulting or Advisory Role - Merck KGaA; Pfizer; QED Therapeutics; Taiho Pharmaceutical
 
Jason Zittel
No Relationships to Disclose
 
Wenjia Wang
No Relationships to Disclose
 
Erika E. Ramsdale
No Relationships to Disclose
 
Vivek Kaul
No Relationships to Disclose
 
John Zebala
Employment - Syntrix Biosystems
Stock and Other Ownership Interests - Syntrix Biosystems
 
David Linehan
No Relationships to Disclose